Recently, the utilization of checkpoint blockade targeting the PD-1/PD-L1 pathway has shown remarkable antitumor responses in patients with advanced melanoma, lung cancer and against other cancers with durable clinical responses23, 24, 25, 26. This evidence concerns the gene PDCD1 and cancer.